THIRD QUARTER IN BRIEF

  • Based on the authorization from the general meeting, the board of directors resolved to carry out a rights issue of approximately SEK 55 million to secure financing of the ongoing and planned development programs (Aug 4)
  • The first part of the multiple dose of laquinimod eye drops in the phase I study has been completed without any serious side effects that can be linked to laquinimod and the study has been expanded with another dose group
  • Active Biotech announces final outcome of the company’s rights issue (Sep 7)

EVENTS AFTER THE END OF THE PERIOD

  • Active Biotech further strengthens the patent protection for laquinimod in eye disorders with a granted patent in US (Oct 24)

Financial summary

SEK MJul-SepJan-SepFull year

2022 20212022 20212021
Net sales-----
Operating profit/loss-13,4-11,3-42,6-33,6-49,8
Profit/loss after tax-13,4-11,2-43,4-33,7-49,8
Earnings per share (SEK)-0,06-0,05-0,19-0,16-0,24
Cash and cash equivalents (at close of period)

55,068,453,1

The report is also available at www.activebiotech.com.

For further information, please contact:

Helén Tuvesson, CEO, +46 46 19 21 56, helen.tuvesson@activebiotech.com
Hans Kolam, CFO, +46 46 19 20 44, hans.kolam@activebiotech.com

About Active Biotech

Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: The wholly owned small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib/IIa for treatment of multiple myeloma. Laquinimod is in a clinical phase I study with a topical ophthalmic formulation, to be followed by phase II-study for treatment of non-infectious uveitis. Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit www.activebiotech.com for more information.

This information is information that Active Biotech is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-11-03 08:30 CET.

Attachments

20221103 Q3 Eng Final

© Modular Finance, source Nordic Press Releases